CLINICAL RESEARCH
Aquaretic Effect of Lixivaptan, an Oral, Non-Peptide, Selective V2 Receptor Vasopressin Antagonist, in New York Heart Association Functional Class II and III Chronic Heart Failure Patients
William T. Abraham, MD*,*,
Alireza A. Shamshirsaz, MD ,
Kim McFann, MD,
Ron M. Oren, MD and
Robert W. Schrier, MD
* The Ohio State University Heart Center, Columbus, Ohio
University of Colorado, Health Sciences Center, Denver, Colorado
University of Iowa Hospitals and Clinics, Iowa City, Iowa
Manuscript received January 11, 2005;
revised manuscript received November 20, 2005,
accepted November 28, 2005.
* Reprint requests and correspondence: Dr. William T. Abraham, The Ohio State University Heart Center, Division of Cardiovascular Medicine, 473 West 12th Avenue, Room 110P DHLRI, Columbus, Ohio 43210-1252 (Email: abraham-1{at}medctr.osu.edu).
OBJECTIVES: The purpose of this study was to examine the renal effects of a V2 receptor arginine vasopressin (AVP) antagonist in heart failure.
BACKGROUND: Arginine vasopressin has been implicated in the renal water retention and dilutional hyponatremia associated with chronic heart failure.
METHODS: We examined the effects of the oral, non-peptide, selective V2 receptor antagonist lixivaptan in 42 diuretic-requiring patients with mild-to-moderate heart failure in a randomized, double-blind, placebo-controlled, ascending single-dose study. After overnight fluid deprivation, patients received single-blind placebo on day –1 (baseline) and double-blind study medication (placebo [n = 12] or lixivaptan 10, 30, 75, 150, 250, or 400 mg [n = 5 per dose group]) on day 1, followed by 4 h of continued fluid restriction and additional 20 h with ad libitum fluid intake.
RESULTS: At all but the 10-mg dose, lixivaptan produced a significant and dose-related increase in urine volume over 4 h, compared with placebo. During 24 h, increases in urine volume ranged from 1.8 l with placebo to 3.9 l after the 400-mg lixivaptan dose (p < 0.01). These increases in urine volumes were accompanied by significant increases in solute-free water excretion. At higher doses, serum sodium was significantly increased; AVP antagonism was well tolerated in these patients.
CONCLUSIONS: These observations confirm a role for AVP in the renal water retention associated with heart failure and suggest that the V2 receptor antagonist lixivaptan may be a promising therapeutic agent for the treatment of heart failure.
|
Abbreviations and Acronyms
| | AQP-2 = aquaporin-2 | | AVP = arginine vasopressin | | CHF = chronic heart failure | | CNS = central nervous system | | ECF = extracellular fluid | | GCRC = General Clinic Research Center | | NYHA = New York Heart Association |
|
This article has been cited by other articles:
|
|
|
|
 
I. Tentzeris, R. Jarai, S. Farhan, T. Perkmann, M. A. Schwarz, G. Jakl, J. Wojta, and K. Huber
Complementary role of copeptin and high-sensitivity troponin in predicting outcome in patients with stable chronic heart failure
Eur J Heart Fail,
July 1, 2011;
13(7):
726 - 733.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Konstam and J. E. Udelson
Hyponatraemia and vasopressin in heart failure: markers or mediators?
Eur J Heart Fail,
March 1, 2011;
13(3):
242 - 244.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. L. Clark, A. P. Coletta, and J. G. F. Cleland
41 Therapeutic control of fluid balance in chronic heart failure
Oxford Textbook of Heart Failure,
January 1, 2011;
1(1):
med-9780199577729-chapter - med-9780199577729-chapter.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. G. Link, G.-X. Yan, and P. R. Kowey
Evaluation of Toxicity for Heart Failure Therapeutics: Studying Effects on the QT Interval
Circ Heart Fail,
July 1, 2010;
3(4):
547 - 555.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Reilly and M. R. Schork
Vasopressin Antagonists: Pharmacotherapy for the Treatment of Heart Failure
Ann. Pharmacother.,
April 1, 2010;
44(4):
680 - 687.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Bower and S. Cox
10.10 Endocrine and metabolic complications of advanced cancer
Oxford Textbook of Palliative Medicine,
January 1, 2010;
4(1):
med-9780198570295-chapter - med-9780198570295-chapter.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R. Zietse, N. van der Lubbe, and E. J. Hoorn
Current and future treatment options in SIADH
Clinical Kidney Journal,
November 1, 2009;
2(suppl_3):
iii12 - iii19.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Finley IV, M. A. Konstam, and J. E. Udelson
Arginine Vasopressin Antagonists for the Treatment of Heart Failure and Hyponatremia
Circulation,
July 22, 2008;
118(4):
410 - 421.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. W. Schrier
Blood Urea Nitrogen and Serum Creatinine: Not Married in Heart Failure
Circ Heart Fail,
May 1, 2008;
1(1):
2 - 5.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Schweiger and M. M. Zdanowicz
Vasopressin-receptor antagonists in heart failure
Am. J. Health Syst. Pharm.,
May 1, 2008;
65(9):
807 - 817.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. P. Rossi
Arginine Vasopressin Receptor Antagonists for Heart Failure: A Winter Climbing to the Everest's Tip?
J. Am. Coll. Cardiol.,
June 5, 2007;
49(22):
2160 - 2162.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Udelson, F. A. McGrew, E. Flores, H. Ibrahim, S. Katz, G. Koshkarian, T. O'Brien, M. W. Kronenberg, C. Zimmer, C. Orlandi, et al.
Multicenter, Randomized, Double-Blind, Placebo-Controlled Study on the Effect of Oral Tolvaptan on Left Ventricular Dilation and Function in Patients With Heart Failure and Systolic Dysfunction
J. Am. Coll. Cardiol.,
June 5, 2007;
49(22):
2151 - 2159.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Q. Khan, O. S. Dhillon, R. J. O'Brien, J. Struck, P. A. Quinn, N. G. Morgenthaler, I. B. Squire, J. E. Davies, A. Bergmann, and L. L. Ng
C-Terminal Provasopressin (Copeptin) as a Novel and Prognostic Marker in Acute Myocardial Infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) Study
Circulation,
April 24, 2007;
115(16):
2103 - 2110.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.H. W. Tang and G. S. Francis
The Year in Heart Failure
J. Am. Coll. Cardiol.,
December 19, 2006;
48(12):
2575 - 2583.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. W. Schrier
Body Water Homeostasis: Clinical Disorders of Urinary Dilution and Concentration
J. Am. Soc. Nephrol.,
July 1, 2006;
17(7):
1820 - 1832.
[Full Text]
[PDF]
|
|
|
|
